Donor cells take on childhood cancers in new safety trial

NCT ID NCT05238792

Recruiting now Disease control Sponsor: Children's National Research Institute Source: ClinicalTrials.gov ↗

First seen Apr 04, 2026 · Last updated May 24, 2026 · Updated 7 times

Summary

This early-phase study tests whether specially trained donor immune cells (TAA-T cells) are safe for children with high-risk solid tumors like neuroblastoma, sarcoma, or Wilms tumor that have come back or not responded to standard treatments. Up to 36 participants will receive cells from a partially matched donor, with close monitoring for side effects. The goal is to find a safe dose and see if the cells can shrink or control the tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Children's National Hospital
RECRUITING

Washington D.C., District of Columbia, 20010, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR